Mark A. Velleca, President and CEO at G1 Therapeutics, Inc. (GTHX), sold 14,500 shares at $35.95 ($522K) on 2018-04-16, disclosed to the SEC on 2018-04-17.
Open-market sale of $522k GTHX by President and CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.95 | 7,000 | $252K | 48.2% |
| 2 | $35.95 | 7,000 | $252K | 48.2% |
| 3 | $36.71 | 500 | $18K | 3.5% |
| Total | $35.98 avg | 14,500 | $522K | 100% |
| Filing → |
| GTHX | SELL | 2022-09-22 | $270K | — | Filing → |
| GTHX | SELL | 2022-08-18 | $1.0M | — | Filing → |
| GTHX | SELL | 2021-07-15 | $946K | — | Filing → |